Clinical trial · Interventional
Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Breast Cancer
NCT01023204CI-TRIAL-00003099completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the efficacy and the safety of paclitaxel given weekly in patients with advanced or recurrent breast cancer
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Paclitaxel | Drug | Paclitaxel | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Paclitaxel
- interventionNames
- Drug: Paclitaxel
Primary outcomes (2)
- measure
- Response rate [defined as total number of patients with complete and partial response divided by number of response-evaluable patients] based on predetermined evaluation criteria
- timeFrame
- Each 49 day course of treatment until withdrawal or unacceptable toxicity
- measure
- Safety: incidence and severity of adverse events, laboratory test abnormalities
- timeFrame
- Each 49 day course of treatment until withdrawal or unacceptable toxicity
Secondary outcomes (1)
- measure
- Duration of response, defined as either Complete or Partial Response, based on Evaluation Criteria on Therapeutic Effects in Patients with Advanced or Recurrent Breast Cancer
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 20 Years
- Maximum age
- 74 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with primary advanced inoperable disease who were refractory to chemotherapy * Patients with recurrent disease following post-operative adjuvant chemotherapy * Patients who were not amenable to post-recurrence chemotherapy Exclusion Criteria: * Patients with serious, uncontrolled medical illness * Patients with previous therapy with taxanes
References
Publications (0)
Data not yet available
No reference posted for this study.